Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers Task Order Title: Sulforaphane for the Prevention of Malignant Mesothelioma
Contract Overview
Contract Amount: $1,199,274 ($1.2M)
Contractor: THE Institute for Cancer Research
Awarding Agency: Department of Health and Human Services
Start Date: 2023-05-03
End Date: 2027-05-02
Contract Duration: 1,460 days
Daily Burn Rate: $821/day
Official Description: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS TASK ORDER TITLE: SULFORAPHANE FOR THE PREVENTION OF MALIGNANT MESOTHELIOMA
Place of Performance
Location: Pennsylvania, 19111